S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Financial Day of Reckoning Has Begun (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
MUST WATCH: Unusual 3-second financial maneuver (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Here's Bill Bonner's "4th and Final Prediction" (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Financial Day of Reckoning Has Begun (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
MUST WATCH: Unusual 3-second financial maneuver (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Here's Bill Bonner's "4th and Final Prediction" (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Financial Day of Reckoning Has Begun (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
MUST WATCH: Unusual 3-second financial maneuver (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Here's Bill Bonner's "4th and Final Prediction" (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Financial Day of Reckoning Has Begun (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
MUST WATCH: Unusual 3-second financial maneuver (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Here's Bill Bonner's "4th and Final Prediction" (Ad)
NASDAQ:ATRA

Atara Biotherapeutics - ATRA Stock Forecast, Price & News

$5.84
+1.19 (+25.59%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.67
$5.87
50-Day Range
$2.85
$8.73
52-Week Range
$2.83
$20.04
Volume
6.25 million shs
Average Volume
3.54 million shs
Market Capitalization
$551.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.57

Atara Biotherapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
244.9% Upside
$20.14 Price Target
Short Interest
Bearish
11.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
0.43mentions of Atara Biotherapeutics in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$243,848 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.10) to ($2.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

382nd out of 1,135 stocks

Biological Products, Except Diagnostic Industry

59th out of 180 stocks

ATRA stock logo

About Atara Biotherapeutics (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ATRA shares. Canaccord Genuity Group lowered their price target on shares of Atara Biotherapeutics from $67.00 to $50.00 in a research report on Wednesday, July 13th. JPMorgan Chase & Co. cut shares of Atara Biotherapeutics from an "overweight" rating to a "neutral" rating and set a $10.00 target price for the company. in a report on Wednesday, July 13th. Citigroup cut shares of Atara Biotherapeutics from a "neutral" rating to a "sell" rating and lowered their target price for the company from $8.00 to $3.00 in a research note on Wednesday, July 20th. The Goldman Sachs Group dropped their target price on shares of Atara Biotherapeutics from $4.00 to $3.00 and set a "sell" rating for the company in a research report on Tuesday, August 9th. Finally, HC Wainwright dropped their price objective on shares of Atara Biotherapeutics from $31.00 to $29.00 and set a "buy" rating for the company in a research note on Monday, May 23rd. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $20.14.

Atara Biotherapeutics Stock Up 25.6 %

Atara Biotherapeutics stock opened at $5.84 on Friday. The company has a fifty day simple moving average of $5.39 and a 200-day simple moving average of $7.95. Atara Biotherapeutics has a 52-week low of $2.83 and a 52-week high of $20.04. The firm has a market capitalization of $551.06 million, a price-to-earnings ratio of -2.29 and a beta of 1.09.

Atara Biotherapeutics (NASDAQ:ATRA - Get Rating) last released its quarterly earnings results on Monday, August 8th. The biotechnology company reported $0.18 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.91) by $1.09. Atara Biotherapeutics had a negative net margin of 344.87% and a negative return on equity of 111.20%. During the same period in the prior year, the business posted ($0.91) EPS. On average, research analysts anticipate that Atara Biotherapeutics will post -3.1 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Pascal Touchon sold 14,220 shares of the firm's stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $7.20, for a total transaction of $102,384.00. Following the transaction, the chief executive officer now directly owns 472,093 shares in the company, valued at $3,399,069.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CFO Utpal Koppikar sold 5,582 shares of the stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $5.32, for a total transaction of $29,696.24. Following the sale, the chief financial officer now owns 207,592 shares of the company's stock, valued at $1,104,389.44. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Pascal Touchon sold 14,220 shares of the business's stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $7.20, for a total transaction of $102,384.00. Following the completion of the sale, the chief executive officer now owns 472,093 shares of the company's stock, valued at $3,399,069.60. The disclosure for this sale can be found here. Insiders sold a total of 40,811 shares of company stock worth $243,848 over the last 90 days. 4.00% of the stock is owned by insiders.

Receive ATRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATRA Stock News Headlines

Atara Biotherapeutics (NASDAQ:ATRA) Upgraded at StockNews.com
Atara Biotherapeutics (NASDAQ:ATRA) Shares Gap Up to $4.65
Atara Biotherapeutics (NASDAQ:ATRA) Price Target Cut to $3.00
Why Atara Biotherapeutics Stock Is Crashing Today
See More Headlines
Receive ATRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATRA Company Calendar

Last Earnings
8/08/2022
Today
8/14/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATRA
Fax
N/A
Employees
578
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.14
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+286.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

Net Income
$-340,140,000.00
Net Margins
-344.87%
Pretax Margin
-344.83%

Debt

Sales & Book Value

Annual Sales
$20.34 million
Book Value
$2.73 per share

Miscellaneous

Free Float
90,588,000
Market Cap
$551.06 million
Optionable
Optionable
Beta
1.09

Key Executives














ATRA Stock - Frequently Asked Questions

Should I buy or sell Atara Biotherapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ATRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATRA, but not buy additional shares or sell existing shares.
View ATRA analyst ratings
or view top-rated stocks.

What is Atara Biotherapeutics' stock price forecast for 2022?

6 brokerages have issued 12-month price targets for Atara Biotherapeutics' shares. Their ATRA share price forecasts range from $3.00 to $50.00. On average, they anticipate the company's share price to reach $20.14 in the next twelve months. This suggests a possible upside of 244.9% from the stock's current price.
View analysts price targets for ATRA
or view top-rated stocks among Wall Street analysts.

How have ATRA shares performed in 2022?

Atara Biotherapeutics' stock was trading at $15.76 at the start of the year. Since then, ATRA stock has decreased by 62.9% and is now trading at $5.84.
View the best growth stocks for 2022 here
.

When is Atara Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ATRA earnings forecast
.

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) issued its quarterly earnings results on Monday, August, 8th. The biotechnology company reported $0.18 EPS for the quarter, beating the consensus estimate of ($0.91) by $1.09. Atara Biotherapeutics had a negative net margin of 344.87% and a negative trailing twelve-month return on equity of 111.20%. During the same period in the prior year, the company posted ($0.91) earnings per share.

What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO?

38 employees have rated Atara Biotherapeutics Chief Executive Officer Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among the company's employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 88.0% of employees surveyed would recommend working at Atara Biotherapeutics to a friend.

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE).

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (9.39%), FMR LLC (6.20%), Northern Trust Corp (0.92%), Healthcare of Ontario Pension Plan Trust Fund (0.65%), Assenagon Asset Management S.A. (0.65%) and Staley Capital Advisers Inc. (0.45%). Insiders that own company stock include Amar Murugan, Jakob Dupont, Joe Newell, Kristin Yarema, Matthew K Fust, Pascal Touchon, Thomas Peterffy and Utpal Koppikar.
View institutional ownership trends
.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atara Biotherapeutics' stock price today?

One share of ATRA stock can currently be purchased for approximately $5.84.

How much money does Atara Biotherapeutics make?

Atara Biotherapeutics (NASDAQ:ATRA) has a market capitalization of $551.06 million and generates $20.34 million in revenue each year. The biotechnology company earns $-340,140,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

How many employees does Atara Biotherapeutics have?

The company employs 578 workers across the globe.

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.atarabio.com. The biotechnology company can be reached via phone at (650) 278-8930 or via email at ehyllengren@atarabio.com.

This page (NASDAQ:ATRA) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.